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Background
Since (limited) health care resources have to be invested
efficiently, HTA/ health technology assessment is
applied ever more often in many health care systems for
‘rational decision-making’. Around 40% to 50% of all
drugs with orphan designation are high-priced oncology
drugs. Within EUnetHTA (an EU-supported project) a
work package deals with the pre-coverage exchange of
early assessments among European countries and the
collaboration on projects for further generation of
evidence.
Methods
Description of methodology of the early assessment of
oncologic drugs and possible mechanisms of exchange
of pre-coverage knowledge within Europe.
Results
A temporary coverage/funding of drugs with orphan sta-
tus often requires additional collection of data on safety,
effectiveness, cost-effectiveness, and the appropriate use
of the drug. Many of the oncology drugs show little (or
marginal effectiveness) at time of approval and reimbur-
sement agencies demand further data before deciding
whether to cover the new drug. Pragmatic clinical trials,
patient access schemes and standard data requirements
on patient relevant outcomes in registries across Europe
are some of the approaches to generate further evidence
and to fill the gap between knowledge on efficacy at
time of approval and demanded knowledge on effective-
ness for coverage decisions. EUnetHTA provides the
necessary structures for coordinated efforts.
Conclusion
Exchanging information on and developing tools to
facilitate evidence generation and collaboration on the
assessment of new costly technologies, many of them
drugs with orphan designation and a reduction of dupli-
cation of assessments is the intention of EUnetHTA.
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